A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

NCT01253564 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: RO5185426

Sponsor

Hoffmann-La Roche